$SPCX has likely seen a short-term bottom...

I used to think cholesterol was simple. High is bad. Low is good. Take a pill. Problem solved. Then I read the Korean study. 14.9 million people. Nine years of follow up. No one on statins. And the result was a U-shape. Very low LDL. More cardiovascular death. Very high LDL. More cardiovascular death. The safest zone sat right in the middle. How can both extremes kill you if the number itself is the problem? Because the number was never the problem. Low LDL weakens your blood vessel walls. Cholesterol builds every cell membrane in your body. It makes your hormones. Drive it to the floor and the body cannot maintain itself. The vessels get fragile. They rupture. High LDL in someone with insulin resistance, chronic inflammation, and a damaged arterial wall is dangerous. Not because LDL attacked the wall. Because it got trapped inside a wall that was already broken. But here is what the system never tells you. A lean, active person eating real food can have LDL of 300 and be one of the healthiest people in the room. High HDL. Low triglycerides. No inflammation. Clean insulin. The LDL is high because their body is running on fat and transporting energy efficiently. Not disease. Metabolism. Same number. Completely different biology. Two people sitting in the same doctor's office. Same LDL on the lab report. One needs intervention. One does not. But both get handed the same prescription. Because the system was built to treat the number. Not understand the environment the number lives in. Stop chasing numbers. Start understanding your body.

A Giant Korean Study of 15 Million People Just Blew a Hole in the “Lower LDL Is Always Better” Story Imagine tracking almost 15 million adults for nearly nine years and counting every death from heart disease and stroke. That’s exactly what Korean researchers did with 14.9 million people who weren’t even taking cholesterol drugs. What they found doesn’t match the simple message that “the lower your LDL, the safer you are.” Instead, the risk formed a U-shape. People with very low LDL died more often from cardiovascular causes, people with very high LDL also died more often, and the sweet spot sat right in the middle. For overall cardiovascular death the lowest risk landed between about 90 and 149 mg/dL. Below that range or well above it, deaths went up. The pattern changed depending on the exact problem. For heart attacks and blocked arteries the best zone was lower (around 70–114 mg/dL). For some types of brain bleeds the risk kept falling only when LDL stayed higher. In plain terms, driving LDL as low as possible protected against one kind of death while raising the risk of others. When the scientists looked only at the higher range (100 to 300 mg/dL) they still saw a clear rise in heart-attack deaths as LDL climbed. Each jump of about 40 mg/dL raised the chance of dying from ischemic heart disease by roughly 26 percent. But that rise was weaker in women and in older adults than in younger men. Even people in their late 70s and early 80s still showed some extra risk from higher LDL for heart attacks and ischemic strokes, yet the overall picture never became “lower is always safer.” The study is huge, it followed real people instead of just guessing from lab tests, and it only looked at folks who were not already on statins. That makes the U-shape harder to wave away. Doctors still treat high LDL when people already have heart disease or several risk factors, because the top end of the curve is real. But the data also show that pushing every healthy adult toward rock-bottom LDL numbers is not free. Too low carried its own price in this massive population. The takeaway is simple and uncomfortable: LDL cholesterol is not a one-way street. In nearly 15 million Koreans the safest zone for dying of cardiovascular disease was not the lowest number on the lab report. Both extremes cost lives. That single finding from one of the largest studies ever done keeps forcing the same awkward question—how low is actually low enough, and for whom?